China Clears Vanflyta for FLT3-ITD Positive AML, Marking a New Option in Targeted Leukemia Care | iPharmaCenter
- Badari Andukuri
- 5 minutes ago
- 1 min read
China’s regulatory authority has approved Vanflyta (quizartinib) for adults with newly diagnosed acute myeloid leukemia (AML) harboring FLT3-ITD mutations, introducing a targeted therapy option into frontline treatment. The drug is to be used alongside standard induction and consolidation chemotherapy, followed by maintenance therapy.
The decision is supported by data from the phase 3 QuANTUM-First study, which showed that adding quizartinib to conventional chemotherapy significantly improved survival outcomes compared with chemotherapy alone.
Patients receiving the combination experienced a meaningful reduction in mortality risk, with median overall survival extending to nearly 32 months versus just over 15 months in the control group.
AML remains one of the most aggressive forms of leukemia, particularly in patients with FLT3-ITD mutations, which are associated with rapid disease progression, higher relapse rates, and poor long-term survival.
In China, AML represents a substantial proportion of leukemia diagnoses, underscoring the need for more effective and targeted treatment approaches.
FLT3 mutations are among the most frequently observed genetic alterations in AML, with internal tandem duplication variants accounting for the majority of cases. These mutations play a central role in driving leukemic cell proliferation, making them an important therapeutic target.
What is Vanflyta (quizartinib) and its mechanism of action?
Quizartinib is an oral inhibitor specifically designed to block FLT3-ITD signaling, aiming to suppress disease activity and improve treatment durability. Its approval adds to a growing shift toward precision medicine in hematologic malignancies, where therapies are increasingly tailored to the genetic profile of the disease.